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Abstract Diabetes mellitus is a chronic metabolic
disease which is a serious global problem. In 2010 an
estimated 285 million people had diabetes and within
the next 20 years this value is expected to almost
double. Many antidiabetic therapies focus on improv-
ing insulin sensitivity, increasing insulin production,
and/or decreasing the level of blood glucose. Although
a number of synthetic medicines are available, drugs
of natural origin have aroused great interest. Triter-
penes seem to demonstrate adequate properties. Many
experiments have shown that these compounds have
several antidiabetic mechanisms. They can inhibit
enzymes involved in glucose metabolism, prevent the
development of insulin resistance and normalize
plasma glucose and insulin levels. These natural
compounds, in contrast to synthetic drugs, apart from
producing a hypoglycemic effect have also been found
to manifest hypolipidemic and anti-obesity activity.
Triterpenes are also promising agents in the preven-
tion of diabetic complications. They have strong
antioxidant activity and inhibit the formation of
advanced glycation end products, implicated in the
pathogenesis of diabetic nephropathy, embryopathy,
neuropathy or impaired wound healing. Until now
very few clinical studies have been concerned with the
application of triterpenes in treating diabetes. How-
ever, due to their great therapeutic potential, these
compounds deserve special attention.
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Triterpenes constitute a large structurally diverse
group of natural compounds biogenetically derived
from active isoprene. Two C15 units build squalene or
related acyclic 30-carbon precursors. As the result of
their cyclization and oxidation, various structures are
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formed. Transformations occur in two ways, one
producing tetra- and pentacyclic triterpenes and the
other one leading through cycloartenole to cucurbita-
cines or to cholesterol and farther to phytosterols,
cardiac glycosides and steroid saponins. The most
common structures of triterpenes include pentacy-
clic—oleanane, ursane, taraxerane, taraxastane, lu-
pane, and tetracyclic—dammarane and cucurbitane
(Fig. 1) (Sticher 2010). Another group consists of
nortriterpenoids formed from tetracyclic triterpene
precursors through oxidation and degradation, result-
ing in fewer than thirty carbon atoms in the basic
skeleton. These are divided into two groups: limonoids
(C26) and quassinoids (C20 and C19) (Harborne and
Baxter 1993).
Triterpenes, especially pentacyclic ones, represent
secondary metabolites that are widely distributed in
the plant kingdom and found in leaves, stem bark,
fruits and roots (Ja¨ger et al. 2009). They are frequently
the object of phytochemical and pharmacological
investigations. The curative potential of triterpenes is
very high yet still poorly recognized. Numerous
in vitro and in vivo studies have revealed their
multidirectional properties: anti-cancer (Laszczyk
2009), antioxidant (Ramachandran and Prasad 2008),
anti-inflammatory (Yasukawa et al. 1996), anti-
Fig. 1 Chemical structures
of the main subclasses of
triterpenes
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atherosclerotic (Sudhahar et al. 2007) or antiviral
(Baltina et al. 2003).
Diabetes mellitus (DM) is a metabolic disease
associated with disrupted insulin secretion or/and
insulin action, resulting in high blood glucose levels.
DM is primarily due to genetic or lifestyle factors, and
creates a numerous therapeutic problems. Untreated
diabetes can be the cause of many complications in
retina, kidney or peripheral nerves and of macrovas-
cular disturbances, such as ischemic heart disease and
stroke (Ban and Twigg 2008). New drugs are still
being sought to treat diabetic patients (Tahrani et al.
2011). Many natural triterpenoids seems to have
promising antidiabetic properties. Their therapeutic
possibilities and mechanisms of action are the subject
of this review.
Molecular target of triterpenes
Triterpenes as a-glucosidase and a-amylase
inhibitors
The therapeutic approach to treating type 2 DM is to
decrease postprandial glucose levels. It can be
achieved through the inhibition of a-glucosidases
and a-amylases which delay the absorbance of carbo-
hydrates in the intestine, leading to a decrease in the
postprandial insulin level (de Sales et al. 2012). There
are many in vitro investigations indicating the ability
of various plant-derived triterpenes to inhibit a-
glucosidase and a-amylase activity.
2,3-seco-20(29)-Lupene-2,3-dioic acid, obtained
from leaves and twigs of Fagus hayatae (Fagaceae),
showed inhibitory activity against a-glucosidase type
IV (from Bacillus stearothermophilus), with IC50
equaling 62.1 lM (the positive control acarbose IC50
23 nM) (Lai et al. 2012). Compounds isolated from the
root bark of Euclea undulate (Ebenaceae), namely a-
amyrin-3O-b-(5-hydroxy) ferulic acid—IC50 7.76 lM
correlating with those of the positive control, acarbose
(IC50 7.35 lM) and lupane—IC50 14.69 lM, have
been found to inhibit a-glucosidase type 1 from
baker’s yeast (Deutschla¨ndera et al. 2011). Corosolic
acid (1-hydroxyursolic acid) isolated from the leaves
of Lagerstroemia speciosa (Lythraceae) shows bioac-
tivity against a-glucosidase from yeast with IC50
3.53 lg/mL, (acarbose IC50 1.82 lg/mL). The
remaining constituents of this plant—maslinic acid,
oleanolic acid and 23-hydroxyursolic acid exhibit a
lower activity where their IC50 equaled 5.52, 6.29 and
8.14 lg/mL, respectively. The research of kinetics
showed that these triterpene acids inhibited the
enzyme uncompetitively (Hou et al. 2009). Pistagre-
mic acid, dammarane type triterpene obtained from
galls of Pistacia chinensis var. integerrima (Anacar-
diaceae), shows potent enzyme inhibitory activity both
against yeast (IC50 89.12 lM, acarbose IC50
780.21 lM) and rat intestinal (IC50 62.47 lM, acar-
bose IC50 38.92 lM) a-glucosidases (Uddin et al.
2012). The binding mode of pistagremic acid to the a-
glucosidase was analyzed using molecular docking
simulations. It has a proper molecular shape and size
for forming hydrogen bonds with an important amino
acid surrounding the catalytic site of this enzyme
(Uddin et al. 2012). Several ursane and oleane type
triterpenes isolated from the roots of Sanguisorba
tenuifolia (Rosaceae) have been found to exhibit dose-
dependent a-glucosidase inhibitory activity and their
IC50 value ranged between 0.62 and 3.62 mM. The
most active inhibitors of the enzyme were euscaphic
acid and p-coumaroylursolic acid whose IC50 values
were 0.67 and 0.62 mM, respectively, comparable
with acarbose having an IC50 value of 0.79 mM
(Kuang et al. 2011). Oleanolic and ursolic acids found
in Phyllanthus amarus (Euphorbiaceae) inhibited
porcine pancreatic a-amylase. The IC50 value for the
mixture of these compounds in the 2:1 ratio was
4.41 lM, however the second compound was much
more active than the first one (Ali et al. 2006).
Oleanane-type triterpene bartogenic acid, isolated
from seeds of Barringtonia racemosa (Lecythida-
ceae), demonstrated moderate inhibitory activity
against both enzymes (a-amylase type VIB from
porcine pancreas and a-glucosidase type I from
baker’s yeast and intestinal enzyme). The IC50 value
of bartogenic acid for the latter enzyme was
168.09 lg/mL (Gowri et al. 2007).
The influence of triterpenes on aldose reductase
Under normoglycemia most cellular glucose is phos-
phorylated into glucose 6-phosphate by hexokinase. A
minor part of nonphosphorylated glucose enters the
alternate route of the glucose metabolism, the so-called
polyol pathway. In the first step of this pathway aldose
reductase catalyzes the reduction of glucose into
sorbitol. In the second step sorbitol is subsequently
Phytochem Rev (2015) 14:675–690 677
123
converted to fructose by sorbitol dehydrogenase
(Cheng and Gonza´lez 1986). Under normoglycemic
conditions aldose reductase might function physiolog-
ically as a general housekeeping enzyme, but under
hyperglycemia, when the metabolism of glucose
through the polyol pathway is significantly increased,
it leads to diabetic microvascular complications (Pe-
trash 2004).
This process can be inhibited by some triterpene
compounds (Fig. 2). Aldose reductase inhibitors were
found among friedelane derivatives (kotalagenin
16-acetate) and isomeric oleanane derivatives (may-
tenfolic acid and 3b,22a-dihydroxyolean-12-en-29-
oic acid), obtained from the roots of Salacia oblonga
(Celastraceae). When they were used at a concentra-
tion of 100 lM the percentage of enzyme inhibition
was 48.2, 54.6 and 75.9 %, respectively (Matsuda
et al. 1999).
Triterpenoids as protein tyrosine phosphatase 1B
(PTP 1B) inhibitors
Protein tyrosine phosphatases are enzymes which
regulate cellular signaling and metabolism (Thareja
et al. 2012). PTPases have been divided into two
broad types, intracellular and transmembrane. PTP
1B belongs to a group of intracellular enzymes
which cause negative regulation of insulin receptors
as well as of the leptin signaling system. They are
responsible for dephosphorylation process of the
receptor b-subunit (Goldstein 2002). Inhibitors of
PTP 1B can potentially ameliorate insulin resistance
and normalize plasma glucose and insulin levels
without inducing hypoglycemia (Thareja et al.
2012). Triterpenes with PTP 1B inhibitory activity
are presented in Table 1 and their molecular target is
demonstrated in Fig. 3.
Some of the natural compounds examined were
more active or had activity similar to RK-682 (IC50
4.5 lM), which was used almost in all experiments as
a positive control. Among the reviewed derivatives
ursolic acid seemed to be the most active. This is
important because it is a widely occuring pentacyclic
triterpene (Sticher 2010).
The structure of the triterpenes plays a key role in
inhibition of PTP 1B. As reported by Na et al. (2006a) and
Kwon et al. (2008) the hydroxyl group at C-3 and the
carboxyl group at C-28 or C-27 of the oleanane-type
triterpenes are essential structural elements related to
inhibitory activity. Similar to triterpenes isolated from
leaves of Rhododendron brachycarpum, the hydroxyl
group at C-3 in the ursane-type also seems indispensable
for enzyme inhibition and the C-28 carboxyl group can
form hydrogen bonds at the PTP 1B catalytic binding site
(Choi et al. 2012). The inhibitory potency appears to
become stronger when the lipophilicity of the tested
compounds was increased (Choi et al. 2012). The main
mode of action of triterpene acids isolated from leaves and
stems of Phoradendron reichenbachianum was through
PTP 1B enzymatic inhibition with the potent, reversible,
selective and linear mixed-type inhibition models, and it is
worth to noticing, that at a concentration of 50 lM
enzyme activity was almost completely stopped (Ram-
ı´rez-Espinosa et al. 2011). All compounds also showed
moderate or weak activity toward other structurally
related PTPases, such as the IF1, IF2 isoenzymes of
human LMW–PTP, yeast LMW–PTP (LTP1) and human
LAR (Ramı´rez-Espinosa et al. 2011). Ursolic acid, apart
from PTP 1B, displayed obvious selectivity for other non-
receptor-type PTPs–TCPTP (T cell protein tyrosine
phosphatase) and SHP2 (src homology phosphatase-2),
with IC50 levels of 3.33 and 2.73 lM, respectively (Zhang
et al. 2006). TCPTP, SHP1 (src homology phosphatase-1)
and SHP2 were also inhibited by corosolic acid, with their
IC50 levels equaling 11.31, 24.56 and 10.50 lM, respec-
tively (Shi et al. 2008).
Ilekudinol A and B isolated from W. subsessilis
inhibited PTP1B in a non-competitive manner. This
observation seems to indicate that a free carboxyl
group at C-28 of 24-norursane triterpenes is essen-
tial to the inhibitory activity towards PTP 1B (Na
et al. 2010). Lupane type triterpenes isolated from
the stem bark of Sorbus commixta also inhibited
PTP 1B in a non-competitive manner (Na et al.
2009).Fig. 2 Inhibitory effect of triterpenes on sorbitol pathway
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14.4 Sambucus adnata (Caprifoliaceae) Sasaki et al. (2011)
3b-Hydroxyolean-12-en-28-oic acid 5.2 Styrax japonica (Styracaceae) Kwon et al. (2008)
3b-Acetoxyolean-12-en-28-acid 7.8
3b-Acetoxyolean-12-en-28-aldehyde 9.3




3.08 Cornus officinalis (Cornaceae) Zhang et al. (2006)
3.8 Symplocos paniculata
(Symplocaceae)
Na et al. (2006b)
4.1 Sambucus adnata (Caprifoliaceae) Sasaki et al. (2011)
3.1 Rhododendron brachycarpum
(Ericaceae)
Choi et al. (2012)





Corosolic acid 7.2 Symplocos paniculata
(Symplocaceae)
Na et al. (2006b)
7.0 Rhododendron brachycarpum
(Ericaceae)









Rhododendric acid 6.3 Rhododendron brachycarpum
(Ericaceae)
Choi et al. (2012)
(20S)-Dammarane-24(25)-ene-3b,20,21-tetrol 15.2 Gynostemma pentaphyllum
(Cucurbitaceae)





Lupeol 5.6 Sorbus commixta (Rosaceae) Na et al. (2009)
Lupenone 13.7
Hopane-6a,22-diol 3.7 Lecidella carpathica
(Lecanoraceae)
Seo et al. (2011)
Brialmontin 1 14.0
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The influence of triterpenoids on glycolytic
and related enzymes
Among glycolytic enzymes, glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH), a key enzyme in
glycolysis, plays a role in membrane fusion, phospho-
transferase activity and apoptosis, whereas glycerol-3-
phosphate dehydrogenase (G3PDH) catalyzes the
reversible biological reduction in glycerone phosphate
using NADH as a reducing equivalent to form
glycerol-3-phosphate (Ishijima et al. 2008).
The influence on these enzymes has been described
for gymnemic acid, which is the mixture of approx-
imately 10 oleanane-type tritepene saponins, found in
leaves of Gymnema sylvestre (Asclepiadaceae). This
mixture inhibited rabbit GAPDH and induced dephos-
phorylation of G3PDH and GAPDH (Fig. 4). It may
have some physiological effects on glucose, glycerol
and lipid metabolisms (Ishijima et al. 2008).
Glycogen phosphorylase inhibitors
The level of glucose is regulated by hepatic glicogen
phosphorylase (GP) catalyzing glycogenolysis result-
ing in an increased hepatic glucose output and
glycogen synthase, which stimulates gluconeogenesis
(Tahrani et al. 2011). GP exists in two interconvertible
forms: dephosphorylated low-activity form, GPb, and
phosphorylated high-activity form, GPa. In both
forms, allosteric effectors can promote equilibrium
between the less active T state and the more active R
state (Oikonomakos et al. 2000). This enzyme is
inhibited by insulin and activated by glucagon and
other counter-regulatory hormones (Tahrani et al.
2011). It has been stated that in diabetes activity of GT
is increased, therefore inhibitors of glycogen phos-
phorylase have been studied as potential therapy for
attenuating hyperglycemia associated with type 2
diabetes (Baker et al. 2005).
Among triterpenes most reports concern oleanane
derivatives as potential GP inhibitors. Several such
compounds were isolated from the roots of Gypsophila
oldhamiana (Caryophyllaceae), with oleanolic acid
and hederagenin being the most active GP inhibitors.
At a concentration of 10 lM both compounds showed
73.07 % of GP inhibition, as compared to a similar
compound, gypsogenin, with 45.11 % inhibition,
whereas the positive control (caffeine in the concen-
tration of 15 lM) showed 50 % inhibition of this
enzyme (Luo et al. 2008). The authors, after compar-
ing this with other compounds, suggest that the
activity depends on the presence of a hydroxyl group
at C-3 and CH3 or CH2OH groups at C-23 in the
oleanane skeleton (Luo et al. 2008). Tormentic acid
and asiatic acid obtained from the whole plant of
Potentilla biscolor (Rosaceae) showed moderate (IC50
90.5 lM, 65.4 lM, respectively), but higher than
caffeine (IC50 158 lM) inhibition of GP (Yang et al.
2010). On the other hand corosolic acid and maslinic
acid were much more potent as liver GP inhibitors
(IC50 101 and 99 lM, respectively) than the positive
control (caffeine, IC50 648 lM) (Wen et al. 2005). The
action of triterpenes on these enzymes is presented in
Fig. 5.
Fig. 3 Triterpenes as PTP 1B inhibitors
Fig. 4 The influence of
gymnemic acid on glycerol
metabolism
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The influence of triterpenes on 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1)
11b-Hydroxysteroid dehydrogenase type I (11b-
HSD1) is the enzyme that converts inactive 11-ketog-
lucocorticoids into active 11b-hydroxyforms in met-
abolically relevant tissues such as the liver, adipose
tissue, skeletal muscles and pancreatic b-cells. Type II
of this enzyme converts active cortisol into inactive
cortisone, thereby preventing inappropriate mineralo-
corticoid receptor activation by glucocorticoids in
aldosterone target tissues such as kidney, colon and
salivary glands. Non-selective inhibition of 11b-HSD
results in serious side-effects such as sodium retention,
hypokalaemia and hypertension (Lipson et al. 2011).
Chronically elevated local glucocorticoid action as a
result of increased 11b-HSD1 activity is associated
with metabolic syndrome, obesity, insulin resistance,
type 2 diabetes mellitus and cardiovascular complica-
tions (Wamil and Seckl 2007). Selective inhibition of
11b-HSD1 has been proposed as a strategy to suppress
glucocorticoid action in tissue specific manner. Many
studies suggest that inhibition or down-regulation of
11b-HSD1 provides a decrease of excessive hepatic
glucose production in hyperglycemia and diabetes
mellitus, and exerts a positive effect on insulin
sensitivity in diabetic subjects (Alberts et al. 2002;
Stulnig and Waldha¨usl 2004; Atanasov et al. 2006).
The ability to selectively inhibit11b-HSD1 (Fig. 6)
has been demonstrated for many semisynthetic (nano-
molar value of IC50) and natural ursane and oleanane
derivatives (Blum et al. 2009). Strong activity has
been exhibited by ursolic acid, 3-epicorosolic acid
methyl ester, tormentic acid methyl ester and 2-ahy-
droxy-3-oxours-12-en-28-oic acid (IC50 1.9, 5.2, 9.4
and 17 lM, respectively) isolated from leaves of
Eriobotrya japonica (Rosaceae) (Rollinger et al.
2010). Interestingly the mixture of these compounds
showed a significantly increased inhibitory potential
on 11b-HSD1. An important role in ligand binding to
the enzyme can be ascribed to carboxylic groups at
C-17 and C-23, hydroxyl groups at C-2 and C-3, with
the 2S,3R configuration seeming to be optimal (Rol-
linger et al. 2010). Constituents of Bursera delpechi-
ana 11-keto-ursolic acid and 3-acetyl-11-keto-ursolic
acid have also been reported as selective inhibitors of
11b-HSD1. Their IC50 values are equal to 2.06 and
1.35 lM, respectively (Rollinger et al. 2010).
The influence of triterpenes on the TGR5 receptor
and its implication in diabetes
TGR5, an emerging G protein-coupled receptor, was
identified as a membrane receptor for bile acids. The
expression of TGR5 and its function are distinct from
Fig. 5 The action of
triterpenes on glycogen
phosphorylase
Fig. 6 The role of triterpenes in cortisone metabolism
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the previously identified nuclear bile acid receptor, the
farnesoid X receptor (FXR). These two bile acid
receptors complement each other in maintaining bile
acid homeostasis and mediating bile acid signaling.
Both receptors also play roles in regulating inflamma-
tion and glucose metabolism (Chen et al. 2011). An
interesting finding for TGR5 is its role in energy
metabolism. The discovery of TGR5 expression in
brown adipocyte tissues (BATs) and the recent
discovery of BAT in the adult human body suggest a
potential approach to combat obesity by targeting
TGR5 to increase thermogenesis. The agonists of this
receptor can also be used for the prevention of the
development of insulin resistance in early stages of
diabetes mellitus (Chen et al. 2011).
Oleanolic acid, a selective TGR5 agonist, which
does not influence FXR is isolated from the leaves of
Olea europaea (Oleaceae) (Sato et al. 2007). Other
compounds with agonistic properties include betulinic
acid and ursolic acid (Genet et al. 2010a). Betulinic
acid is the most active (83 % efficacy with respect to
litocholic acid used as positive control) of these three
triterpenes mentioned above. The values of EC50 for
oleanolic, betulinic and ursolic acids were 2.25; 1.04;
1.43 lM, respectively (Genet et al. 2010a). A com-
parison with other compounds having similar structure
has proven that the hydroxyl group at C-3 plays a role
in this type of activity. Unfortunately oleanolic acid
has weak metabolic stability when administrated
orally to rats and very low bioavailability (Sato et al.
2007; Genet et al. 2010a, b).
Nomilin, a highly oxygenated limonoid-type triter-
pene specific for Citrus sp., has also been recognized
as an activator of TGR5. Its influence on TGR5 was
higher than the natural agonist, chenodeoxycholic
acid. Similar to the compounds mentioned above it
does not induce FXR activity. Experimental animals
treated with nomilin (0.2 %) had a lower body weight,
decreased serum glucose and serum insulin, and an
enhanced glucose tolerance (Ono et al. 2011).
Tests on the antidiabetic activity of triterpenes
Experiments on the antidiabetic potential of natural
products are carried out mainly in vivo, and are often
complemented with in vitro studies to explore the
mechanism of action of extracts or isolated com-
pounds. Among animal models of DM those with
pharmacologically induced diabetes and surgical or
genetic models of diabetes are used. In vitro studies
concern mainly insulin secretion and glucose uptake
(Fro¨de and Medeiros 2008).
Many crude extracts of plants and isolated triterp-
enoids have been tested with regard to their antidia-
betic and antihyperglycemic activity. Table 2 presents
various cell models and Table 3 shows animal models
adapted to test the antidiabetic activity of triterpenes.
The result of this review demonstrate that triter-
penes often exert an effect on insulin biosynthesis,
secretion and signaling. Additionally they also prevent
pancreatic b-cell function, regulate total cholesterol
and triglicerides level and body weight.
Terpenoid sweetness inhibitors
It has been observed that subjects whose perception of
sweetness had been decreased reduced consumption of
total calories and sweet calories. This could be
important in the prevention of uncontrolled glucose
level elevation (Brala and Hagen 1983).
Sweetness inhibitors of terpenoid origin have been
identified in some plants. These compounds were
initially isolated from the leaves of Gymnema sylves-
tre and include oleanane-type saponins: gymnemic
acid I–VI, X–XVIII and gymnema saponins. Unlike
glycosides their aglycones are inactive. Such com-
pounds, including ziziphin, jujubasaponins II–VI and
dammarane type saponins are found in Ziziphus jujuba
(Rhamnaceae). Dammarane derivatives, such as ho-
dulcin, hodulosides I–IX and jujuboside B can be
isolated from Hovenia dulcis (Rhamnaceae). Interest-
ingly, the time for the recovery of the ability to taste
sweetness differs for compounds from every plant. For
G. sylvestre it is 15 min–24 h, for Z. jujube it is
5–10 min and for H. dulcis it is 1–4 min (Suttisri et al.
1995).
Reduction of diabetes mellitus complications
Antioxidants in diabetes mellitus
It has been shown in various studies that diabetes
mellitus is associated with the increased formation of
free radicals and a decrease in antioxidant potential
(Rahimi et al. 2005). Oxidative stress induced by
682 Phytochem Rev (2015) 14:675–690
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hyperglycemia and free fatty acids causes insulin
resistance, b-cell dysfunction, and late diabetic com-
plications (Evans et al. 2002; Manna et al. 2009).
Figure 7 shows disorders triggered by oxidative stress
in kidney and serum.
The application of antioxidants especially of nat-
ural origin is one of the strategies in treating DM
(Rahimi et al. 2005). Triterpenes play an important
role as plant antioxidants. Ursolic acid exhibited
hydroxyl radical scavenging activity, perhaps through
its hydrogen donating ability. It also scavenged
superoxide anions (Ramachandran and Prasad 2008).
Corosolic acid reduced levels of thiobarbituric acid-
reactive substance (TBARS) and 8-hydroxydeoxygu-
anosine (8-OHdG), both of which are oxidative stress
biomarkers (Yamaguchi et al. 2006). Arjunoic acid
present in the bark of Terminalia arjuna showed
considerable activity against oxidative processes. This
oleanane derivative prevented alternation of STZ-
induced intracellular RNS and ROS formation in
spleen tissue, deactivated the polyol pathway,
enhanced the level of IL-2 and IFN-c and decreased
the level of TNF-a (Manna et al. 2010). The lupane-
type triterpene, bacosine, obtained from the herb of
Bacopa monnieri (Scrophulariaceae) also displayed
antioxidant properties. This compound significantly
decreased the level of malonylaldehyde, increased the
level of glutathione (GSH) and the activity of super-
oxide dismutase (SOD) and catalase (CAT) in the liver
of diabetic rats (Ghosh et al. 2011).
Table 2 In vitro studies on antidiabetic activity of triterpenes
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Table 3 Antidiabetic activity of triterpenes tested in animal models
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The importance of triterpenes in AGE synthesis
and in relieving complications provoked by them
In the etiology of diabetic vascular complications a
major role is played by advanced glycation end
products (AGEs) produced by non-enzymatic glyca-
tion and oxidation of proteins and lipids. AGEs have
been implicated in the pathogenesis of diabetic
nephropathy, embryopathy, neuropathy or impaired
wound healing and independently may predict cardio-
vascular morbidity and stroke in the diabetic popula-
tion (Ahmed 2005). Resulting AGEs activate the
receptor for advanced glycation end products
(RAGE). Activation of RAGE by AGEs causes
upregulation of the transcription factor NF-jB and
its target genes. Binding of AGEs to RAGE induces a
cascade of processes leading to damage of arteries in
diabetic patients (Goldin et al. 2006). The role of
RAGE has been observed in the development of
accelerated atherosclerosis associated with diabetes
(Basta et al. 2004).
Some triterpene compounds possess the ability to
suppress formation of AGEs and are promising agents
in the prevention and treatment of DM complications.
Ursolic acid as a strong antioxidant suppressed
oxidative stress and ameliorated vascular injury in
STZ-induced diabetic rats through inhibition of acti-
vation of the RAGE-NADPH oxidase-NF-jB signal
transduction pathway (Xiang et al. 2012).
The effect of oleanolic acid and ursolic acid on
AGEs production in renal tissue has been examined.
Following treatment of STZ-diabetic mice with these
compounds renal aldose reductase activity was sup-
pressed and glyoxalase I activity was enhanced, which
contributed to a decrease in renal AGEs formation and
an improvement of renal functions (Wang et al. 2010).
Oleanolic acid is a strong inhibitor of the formation of
glycative products in vitro (Yin and Chan 2007). Also
astragalosides and dammarane-type saponins from
Astragalus membranaceus (Fabacea) were found to
have an impact on the production of AGEs. An in vitro
test showed astragaloside V to have the strongest
inhibitory effect of several isolated compounds (Mo-
tomura et al. 2009).
Other possibilities of triterpenes use
When HFD-diabetic mice were treated with ursolic
acid at a concentration of 0.2 %, monocyte chemo-
tactic activity was decreased in correlation with the
extent of reduction in atherosclerotic lesion formation.
This compound reduced monocyte transmigration and
macrophage recruitment. The results suggest that
ursolic acid protects monocytes from metabolic stress
and inhibits the transformation of healthy monocytes
into a hyper-chemotactic phenotype (Ullevig et al.
2011). Ursolic acid administrated to insulin-deficient
diabetic mice at a dose of 0.01 %, as a food
supplement prevented diabetic nephropathy through
significant inhibition in 75 % of glomerular hypertro-
phy and suppression of type IV collagen accumulation
in glomeruli. It also suppressed diabetes-induced
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activation of STAT-3, ERK1/2 and JNK pathways,
and iNOS overexpression in kidney tissue (Zhou et al.
2010). A neuroprotective effect was observed in
hyperglycemic rats treated with maslinic acid (5 or
50 mg/kg b.w.) after focal cerebral ischemia. A
reduction in infarct volumes, improvement of neuro-
logical scores and enhancement of the glial glutamate
transporter (GLT-1) expression at the protein and
mRNA levels have been proven (Guan et al. 2011). A
mixture of triterpene acids (with ursolic acid and
oleanolic acid as main components) isolated from
Cornus officinalis (Cornaceae) fruit suppressed upreg-
ulation of mRNA expression of the endothelin system,
iNOS and other disorders of this type involved in the
development of vascular abnormalities and retinopa-
thy (Su et al. 2007).
Bioavailability and toxicity of triterpenes
Triterpenes are large molecules and their penetration
through cell membranes can be difficult. However,
experiments revealed that they permeate into cells,
even over the blood–brain barrier, and accumulat in
large amounts in the liver. Moreover, chronic intake of
triterpene-rich natural products increases their bio-
availability and accumulation in circulation and tissues
(Yin et al. 2012). It has been observed that the
bioavailability of triterpenes can be improved by
combining them with cyclodextrins (Cerga et al. 2011).
Natural medication mainly requires repeated intake
of high doses of the substance. Therefore, toxicity of
maslinic acid has been examined. The results obtained
from acute and chronic intake of this compound
indicate that it does not exhibit any adverse effects
on the variables tested in mice (Sanchez-Gonzalez
et al. 2013).
Future of triterpenes as antidiabetic agents
A review of literature revealed a multidirectional
effect of triterpenes. However, plants rich in these
compounds are mainly applied in folk medicine, with
an exception of the extract from the leaves of
Lagerstroemia speciosa, containing corosolic acid as
the main component. The extract is available as the
preparation GlucosolTM, standardized to contain 1 %
corosolic acid (Judy et al. 2003).
Triterpenes can become prototypes for anti-diabetic
drugs. Based on the triterpene skeleton derivatives
which are more active than their substrates can be
synthesized, e.g. oleanolic acid dihydroxy-olide is a
stronger a-glucosidase inhibitor than the initial sub-
stance (Ali et al. 2002) and a derivative obtained in the
reaction of maslinic acid with 1,4-dibromobutane is a
more potent glycogen phosphorylase inhibitor than
maslinic acid itself (Wen et al. 2006).
Conclusion
The majority of the plants described above containing
triterpene compounds are used in various countries in
traditional medicine as antidiabetic remedies. Con-
temporary experiments confirm their activity and, in
many cases, explain the mechanisms. Selected triter-
penes could become important remedies for curing
diabetes mellitus and are promising compounds for the
development of new multitarget bioactive drugs. The
use of triterpenes as AGEs inhibitors may be a
potentially effective strategy to prevent diabetic
complications. Their activity has been demonstrated
in a number of in vitro studies and on animal models,
but continuous clinical research does not exist.
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